Birch pollen allergy immunotherapy - LETI Pharma

Drug Profile

Birch pollen allergy immunotherapy - LETI Pharma

Alternative Names: Depigmented Glutaraldehyde Polymerized Birch Pollen Allergenic Extract; Depigoid Birch; Depigoid Birch 5000

Latest Information Update: 09 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator LETI Pharma GmbH
  • Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rhinoconjunctivitis; Seasonal allergic rhinitis
  • No development reported Atopic dermatitis

Most Recent Events

  • 09 Oct 2015 No recent reports on development identified - Phase-III for Rhinoconjunctivitis (In adolescents, In children, In adults) in Sweden (SC)
  • 09 Oct 2015 No recent reports on development identified - Phase-III for Seasonal allergic rhinitis (In adolescents, In children, In adults) in Sweden (SC)
  • 14 Aug 2015 No recent reports on development identified - Phase-II for Atopic dermatitis in Germany (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top